Our History
navigate_next About us navigate_next
A young but broad-shouldered company.
Birth
As part of the SAVIO Group, of which Savio Pharma Italia is now part of it, the idea emerged to establish a company aimed to at promoting the Group's price list addressed to the medical specialist, with a core mission to provide high-quality scientific information.
A business division is established, acquiring approximately 110 medical representatives primarly focused on specialty medicine
The branch of scientific information
Our partners
An important agreement is signed with the GlaxoSmithkline Pharmaceutical Group for the sales license of the oral amoxicillin/clavulanic acid antibiotic "Clavulin," a collaboration that continuos to this day. In the same year, a potent corticosteroid ("Decadron"), is launched on the market, which was later included in September 2020 by EMA among the treatment options for patients with COVID-19.
The market launch of the first slow-release metformin ("Slowmet") which gradually becomes a benchmark in the treatment of type II diabetes mellitus.s.
Launch of the first slow-release metformin
Market launch of the specialty Annister
The market launch "Annister", a specialty for the prevention and treatment of vitamin D deficiency.
Membership in the Italian Association of Drug Companies, called “Farmindustria”
Farmindustria
Savio Pharma Italia
The company adopts today's name, Savio Pharma Italia.
In response to the pandemic, Savio Pharma Italia enhanced its Remote Medical Scientific Information System, which had been developed alongside the traditional ISF System. The remote ISF network, consisting of 13 scientific medical representaives continuous to operate in Italy in synergy with the traditional ISF line.
The response to the pandemic
SAVIO Group
Restructuring of the SAVIO Group, with the aim of increasing the value and performance of the Group's various enterprises, in which Savio Pharma Italia is positioned as the quality ally of the medical class.
